Evidence map›Paper›PMID 39941162›Full record

ArticleInternational journal of molecular sciences2025

Optimising Aripiprazole Long-Acting Injectable: A Comparative Study of One- and Two-Injection Start Regimens in Schizophrenia with and Without Substance Use Disorders and Relationship to Early Serum Levels.

Giada Trovini, Ginevra Lombardozzi, Georgios D Kotzalidis, Luana Lionetto, Felicia Russo, Angela Sabatino, Elio Serra, Simone Castorina, Giorgia Civita, Sara Frezza and 6 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Giada TroviniClinica Villa von Siebenthal Neuropsychiatric Hospital, Via della Madonnina 1, 00040 Rome, Italy.
Ginevra LombardozziClinica Villa von Siebenthal Neuropsychiatric Hospital, Via della Madonnina 1, 00040 Rome, Italy.ORCID 0009-0002-7039-1820
Georgios D KotzalidisClinica Villa von Siebenthal Neuropsychiatric Hospital, Via della Madonnina 1, 00040 Rome, Italy.
Luana LionettoClinical Biochemistry, Mass Spectrometry Section, Sant'Andrea University Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
Felicia RussoSPDC DSM ASL BA (SPDC Ospedale Santa Maria Degli Angeli), P.za Padre Pio 21, 70017 Putignano, Italy.ORCID 0009-0002-2306-6830
Angela SabatinoDSM ASL Viterbo Distretto C (CSM Civita Castellana), via Francesco Petrarca snc, 01033 Civita Castellana, Italy.ORCID 0009-0009-5553-648X
Elio SerraAzienda Sanitaria Locale Lecce, UOC CSM Nardò, Via XXV Luglio, 4, 73048 Nardò, Italy.
Simone CastorinaClinica Villa von Siebenthal Neuropsychiatric Hospital, Via della Madonnina 1, 00040 Rome, Italy.ORCID 0009-0008-1204-3282
Giorgia CivitaClinica Villa von Siebenthal Neuropsychiatric Hospital, Via della Madonnina 1, 00040 Rome, Italy.
Sara FrezzaClinica Villa von Siebenthal Neuropsychiatric Hospital, Via della Madonnina 1, 00040 Rome, Italy.
Donatella De BernardiniClinical Biochemistry, Mass Spectrometry Section, Sant'Andrea University Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
Giuseppe CostanziClinical Biochemistry, Mass Spectrometry Section, Sant'Andrea University Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
Marika AlborghettiClinica Villa von Siebenthal Neuropsychiatric Hospital, Via della Madonnina 1, 00040 Rome, Italy.
Maurizio SimmacoClinical Biochemistry, Mass Spectrometry Section, Sant'Andrea University Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
Ferdinando NicolettiDepartment of Physiology and Pharmacology "Vittorio Erspamer", Faculty of Medicine and Pharmacy, University of Rome "La Sapienza", Piazzale Aldo Moro 5, 00185 Rome, Italy.
Sergio De FilippisClinica Villa von Siebenthal Neuropsychiatric Hospital, Via della Madonnina 1, 00040 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aripiprazole as a long-acting injectable (LAI) is initiated in oral aripiprazole-stabilised patients and needs, after first injection, 14 days supplementation of oral aripiprazole (one-injection start, OIS). Recently, an alternative two-injection start (TIS) was advanced, involving two 400 mg injections with a single 20 mg oral supplementation of aripiprazole. We tested the two regimens in patients with schizophrenia (SCZ,

Indexed as

Antipsychotic AgentsAripiprazoleSchizophreniaSubstance-Related DisordersAdultDelayed-Action PreparationsFemaleHumansInjectionsMaleMiddle AgedPiperazinesQuality of LifeQuinolonesTreatment OutcomeAntipsychotic AgentsAripiprazoledehydroaripiprazoleDelayed-Action PreparationsPiperazinesQuinolonesaripiprazole long-acting injectablearipiprazole serum levelsclinical courselong-acting injectable antipsychoticsmedication adherenceschizophreniasingle injection startsubstance use disorderstherapeutic drug monitoringtwo-injections start

Identifiers

PMID39941162
PMCPMC11818917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.